title: [Treatment of atrophic and irritative vulvovaginal symptoms with an anhydrous lipogel and its complementary effect with vaginal estrogenic therapy: new evidences].
abstract: It is sometimes difficult to treat vulvovaginal itching and dryness, which represent frustrating symptoms for both patients and doctors. In case that the etiological agent is Candida albicans, effective antimycotic therapies are available; however, itching is often caused by aspecific allergic-irritative factors, which are difficult to be defined. In these cases, patients are invited to limit local irritative factors; nevertheless, this advice is not always taken and sometimes it turns out to be insufficient. Besides behavioral suggestions, a therapeutic support would be useful; medical doctors habitually prescribe local symptomatic treatments which, however, do not target numerous causes of irritative vulvovaginal symptomatology, though they are formulated for vulvovaginal application. If there is estrogenic deficit, the best therapeutic approach is based on topical estrogenic therapy, which is sometimes ineffective on vulvar symptoms. Frequently, it is necessary to choose a complementary therapeutic tool for vaginal application in order to alleviate itching, burning, erythema, dryness. The aim of this study was to evaluate the efficacy of an innovative anhydrous lipogel containing vitamin E and boswellic acids. Results of this study, performed on 34-58-year-old patients, confirmed the efficacy of the lipogel on irritative vulvovaginal symptoms. In postmenopausal women, the lipogel is a useful synergistic complement to topical hormonal therapy.
authors.affiliation: Oncologia Ginecologica, Istituto Nazionale Tumori, Centro di Riferimento Oncologico. Aviano, Pordenone, Italia.
authors.forename: L
authors.initials: L
authors.lastname: Del Pup
mesh_terms: D000282:Administration, Intravaginal; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D001284:Atrophy / Q000188:drug therapy; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage*; D008055:Lipids / Q000008:administration & dosage*; D009824:Ointments / Q000008:administration & dosage; D011537:Pruritus / Q000188:drug therapy; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome; D014315:Triterpenes / Q000008:administration & dosage; D014810:Vitamin E / Q000008:administration & dosage; D014848:Vulvovaginitis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000935:Antifungal Agents; D004338:Drug Combinations; D004967:Estrogens; D008055:Lipids; D009824:Ointments; D014315:Triterpenes; D014810:Vitamin E; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; C054625:boswellic acid